Biotechnology

Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

* TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate * Safety profile was favorable and ...

2021-12-12 09:00 5419

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Dec. 10, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.       Located in Minsk, capital of the Republic of Belarus a...

2021-12-10 23:38 4552

Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx

SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...

2021-12-10 15:15 4265

Trajan to acquire LEAP PAL Parts

MELBOURNE, Australia, Dec. 9, 2021 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has entered into a binding agreement to acquire the business of LEAP PAL Parts and Consumables, LLC ("LPP"), based in Raleigh North Caro...

2021-12-09 21:00 1761

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization

MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ --  Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which willinvestigate the use of angiography-based vessel fractional ...

2021-12-09 21:00 2610

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...

2021-12-09 20:00 2184

Frost & Sullivan Honors Disruptive Organizations in the Region with Prestigious Industry Awards

16 companies will be recognized at the final Frost & Sullivan Virtual Awards Ceremony of the year, which will be broadcasted live on YouTube at6:00 p.m. (GMT +8),16 December 2021. SINGAPORE, Dec. 9, 2021 /PRNewswire/ -- Frost & Sullivan Best Practices Awards will be honoring 16 leading organizat...

2021-12-09 19:32 2131

Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights today named Lunit to its third annual Digital Health 150 , which showcases the 150 most promising private digital healt...

2021-12-09 11:24 2050

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...

2021-12-09 08:00 2064

Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

NEW YORK and HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021.  This presentation w...

2021-12-08 20:00 2384

China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again

NANJING, China, Dec. 8, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio at the opening ceremony announced thatthe largest commercial GMP plasmid manufacturing facility in ...

2021-12-08 18:22 2103

Nippon Express (Nederland) Acquires GDP Compliance Certification for Company-owned Warehouse

TOKYO, Dec. 8, 2021 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NEN"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification, effectiveSeptember 6, for its company-owned warehouse in Schiphol Trade Park nearAmsterdam's Schiphol ...

2021-12-08 14:00 1277

GSK Provides Update on Manufacturing Operations in Singapore

SINGAPORE, Dec. 8, 2021 /PRNewswire/ -- GSK announced today that it will cease manufacturing and outsource all production of amoxicillin that is currently produced at its Quality Road site inSingapore. Amoxicillin is an active pharmaceutical ingredient (API) in GSK's Augmentin product. This will ...

2021-12-08 09:30 3679

Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemot...

2021-12-08 08:30 2848

CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants

SUMMARY CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19. Its active pharmaceutical ingredient is niclosamide, an anthelmintic drug, and is expected to work on var...

2021-12-07 22:00 2192

Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual Gene...

2021-12-07 21:35 2471

Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual Gene...

2021-12-07 21:32 2518

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the "Board") ...

2021-12-07 21:00 3038

Sino Biological newly launched a panel of research reagents for SARS-CoV-2 Omicron variant

BEIJING, China, Dec. 7, 2021 /PRNewswire/ -- Sino Biological, Inc. ( http://www.sinobiological.com ; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which qu...

2021-12-07 18:18 2404

Samsung Biologics adds to global ISO certifications with Quality Management System

* Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle * The company is fully certified with the recognition across all of its CDO, CMO and all other core business units in Plant 1,2, a...

2021-12-07 13:04 1560
1 ... 191192193194195196197 ... 299